News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Novo Nordisk A/S’s (Jobs) Levemir Has Mixed Results in Diabetes Study
September 21, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Reuters) - Patients with type 2 diabetes are less likely to reach target blood sugar levels on Novo Nordisk's long-lasting insulin Levemir than on shorter-acting products, researchers said on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
Novo Nordisk
MORE ON THIS TOPIC
Job Trends
Biopharma needs to reward scientists’ judgment
September 30, 2026
·
5 min read
·
Joanna Ghayad
Huntington’s disease
UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years
September 29, 2026
·
4 min read
·
Heather McKenzie
Obesity
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
September 29, 2026
·
2 min read
·
Tristan Manalac
Business
Summit snags $2B investment from AstraZeneca, clearing financial overhang
September 29, 2026
·
3 min read
·
Tristan Manalac
